HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

October 30, 2026

Conditions
HCC - Hepatocellular Carcinoma
Interventions
DRUG

PD-L1 inhibitor: Adebrelimab Injection;Regorafenib Tablets

"PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses."

All Listed Sponsors
lead

Yehua Shen

OTHER